News Jo’s story: Staying connected to nature Jo describes the importance of staying connected to nature for her mum Sue, who is living with mixed dementia.
Blog My Love, My Pet: exploring love, loss, memory and death at the Fringe Rob Gaetano tells us about his one-man show at the Fringe which he created to explore his fears around growing old and developing dementia.
Blog Sean's story Sean is 55 years old and from the north of Scotland. He living well with a diagnosis of vascular dementia. His advice is to be determined to live your life. This is his story.
Content Page Cash collections We aim to make it as easy as possible for you to send us the money from your collection.
Content Page Make a one off donation by PayPal Making a one off donation via PayPal is just one of the many ways you can donate to Alzheimer Scotland. PayPal is an easy, secure way to donate and help us make sure nobody faces dementia alone.
Blog Reflecting on a year of support Our Executive Lead for Localities, Geraldine Ditta, reflects on the way our frontline teams have supported people with dementia and their families and carers since March 2020, pays tribute to our wonderful volunteers, and looks to the future of Alzheimer Scotland’s support.
News Fitness enthusiast raises funds for Alzheimer Scotland Ricky’s mother-in-law, Anne, was diagnosed with dementia last year. Now, the fitness enthusiast has set himself a series of endurances challenges to raise vital funds for Alzheimer Scotland.
Fundraising Running Men's 10k Glasgow 2025 This is your time to set your next challenge and be part of something special at the Men’s 10k Glasgow!
Fundraising Running Men's 10k Edinburgh 2025 This is your time to set your next challenge and be part of something special at the Men’s 10k Edinburgh 2025!
News Our response to UK health regulator’s rejection of donanemab treatment for Alzheimer’s disease Today, the UK’s medicines regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), approved a second Alzheimer’s drug, donanemab, for use in the UK. However, an interim provisional decision by the National Institute for Health and Care Excellence (NICE) has deemed donanemab not cost-effective for the NHS. As a result, for now at least, the drug will only be available privately.
